Atom Investors LP Raises Position in Compugen Ltd. (NASDAQ:CGEN)

Atom Investors LP grew its holdings in shares of Compugen Ltd. (NASDAQ:CGEN) by 27.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 151,816 shares of the biotechnology company’s stock after purchasing an additional 32,701 shares during the quarter. Atom Investors LP owned approximately 0.17% of Compugen worth $275,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in CGEN. Rothschild Investment LLC purchased a new position in shares of Compugen in the 2nd quarter worth $380,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Compugen by 82.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock worth $497,000 after buying an additional 124,190 shares during the period. ARK Investment Management LLC raised its position in shares of Compugen by 4.7% in the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock worth $1,850,000 after buying an additional 48,979 shares during the period. Secure Asset Management LLC purchased a new position in shares of Compugen in the 2nd quarter worth $69,000. Finally, Joel Isaacson & Co. LLC raised its position in shares of Compugen by 136.4% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock worth $94,000 after buying an additional 30,000 shares during the period. 12.22% of the stock is owned by hedge funds and other institutional investors.

Compugen Trading Up 3.2 %

Shares of NASDAQ CGEN opened at $1.59 on Thursday. Compugen Ltd. has a 12-month low of $0.71 and a 12-month high of $3.03. The company has a market cap of $141.89 million, a P/E ratio of 77.00 and a beta of 2.59. The stock has a fifty day moving average price of $1.66 and a 200 day moving average price of $1.82.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.20). Compugen had a net margin of 2.67% and a return on equity of 2.62%. The company had revenue of $17.13 million during the quarter, compared to analyst estimates of $17.67 million. During the same quarter in the prior year, the company posted ($0.11) earnings per share. On average, sell-side analysts forecast that Compugen Ltd. will post 0.11 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.